The 2022 revision of EU GMP Annex 1 (Manufacture of Sterile Medicinal Products) has a heavy focus on Contamination Control Strategy (CCS). PDA TR-82 is explicitly cited in the industry’s interpretation of Annex 1 for biologic products.
Key overlaps include:
If your site is implementing Annex 1, you cannot do so fully without the PDA Technical Report 82 PDF open on your desk. pda technical report 82 pdf
For drug developers, TR‑82 changes the conversation from “Did we see LER?” to “What is our LER control strategy?” Key takeaways include:
Endotoxin aggregation requires magnesium (Mg²⁺) and calcium (Ca²⁺) ions. Formulations containing chelators like EDTA strip these ions, causing endotoxins to disaggregate into sub-detection monomers that are inactive in the LAL test but may still be in vivo pyrogenic. The 2022 revision of EU GMP Annex 1
Formally titled "Low Bioburden and Aseptic Filtration of Mammalian Cell Culture Broths," PDA TR-82 was published to address a critical gap in existing regulatory guidance. While standard PDA reports (like TR-26 on sterilization filtration) focus heavily on final product sterilization, TR-82 zooms in on the unique challenges of the upstream and midstream bioprocessing steps.
Based on the recommendations in the PDF, here is how to operationalize the report: If your site is implementing Annex 1, you
LER occurs when a product formulation causes endotoxin to mask, aggregate, or bind to particulates or container surfaces, rendering it invisible to the standard kinetic chromogenic or turbidimetric assays—without losing its biological activity. Classic culprits include:
Simply put: the test says “pass,” but the risk remains.